Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 28.75 +0.14 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.61 | 52 Week High | $5.17 | |||
| Open | $28.50 | 52 Week Low | $0.94 | |||
| Day High | $29.28 | P/E | N/A | |||
| Day Low | $28.49 | EPS | $0.00 | |||
| Volume | 1,155,525 | |||||
